Pneumonia

>

Latest News

UPDATE: ACIP Vote Unanimous to Recommend Merck 21-Valent Pneumococcal Shot for Older Adults / image credit - pneumonia in alveoli: ©Kateryna Kon/stock.adobe.com
UPDATE: ACIP Vote Unanimous to Recommend Merck 21-Valent Pneumococcal Shot for Older Adults

July 1st 2024

The novel vaccination is recommended as an option for adults aged 65 years and older who have not received a pneumococcal conjugate vaccine.

FDA Approves Merck's 21-Valent Pneumococcal Vaccine for Adults 50 Years of Age and Older: A First and Long-Awaited
FDA Approves Merck's 21-Valent Pneumococcal Vaccine for Adults 50 Years of Age and Older: A First and Long-Awaited

June 18th 2024

Older, Mentally Altered Adults at Greatest Risk for Inappropriate Diagnosis of CAP
Older, Mentally Altered Adults at Greatest Risk for Inappropriate Diagnosis of CAP

April 5th 2024

©Kateryna_Kon/stock.adobe.com
Merck's 21-Valent Adult-Specific Pneumococcal Vaccine Accrues New Phase 3 and Real World Data

March 19th 2024

FDA Grants Priority Review to Merck BLA for Investigational 21-Valent Pneumococcal Vaccine December 19, 2023
FDA Grants Priority Review to Merck BLA for Investigational 21-Valent Pneumococcal Vaccine

December 19th 2023

Video Interviews

More News

© 2024 MJH Life Sciences

All rights reserved.